Expert Review of Anti-infective Therapy最新文献_第10页

Hospital-acquired bacterial pneumonia in critically ill patients: from research to clinical practice. 重症患者在医院获得的细菌性肺炎：从研究到临床实践。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-20 DOI: 10.1080/14787210.2024.2354828

Pompeo Costantino Kouroupis, Niall O'Rourke, Sinead Kelly, Myles McKittrick, Elne Noppe, Luis F Reyes, Alejandro Rodriguez, Ignacio Martin-Loeches

{"title":"Hospital-acquired bacterial pneumonia in critically ill patients: from research to clinical practice.","authors":"Pompeo Costantino Kouroupis, Niall O'Rourke, Sinead Kelly, Myles McKittrick, Elne Noppe, Luis F Reyes, Alejandro Rodriguez, Ignacio Martin-Loeches","doi":"10.1080/14787210.2024.2354828","DOIUrl":"10.1080/14787210.2024.2354828","url":null,"abstract":"Introduction: Hospital-acquired pneumonia (HAP) represents a significant cause of mortality among critically ill patients admitted to Intensive Care Units (ICUs). Timely and precise diagnosis is imperative to enhance therapeutic efficacy and patient outcomes. However, the diagnostic process is challenged by test limitations and a wide-ranging list of differential diagnoses, particularly in patients exhibiting escalating oxygen requirements, leukocytosis, and increased secretions.Areas covered: This narrative review aims to update diagnostic modalities, facilitating the prompt identification of nosocomial pneumonia while guiding, developing, and assessing therapeutic interventions. A comprehensive literature review was conducted utilizing the MEDLINE/PubMed database from 2013 to April 2024.Expert opinion: An integrated approach that integrates clinical, microbiological, and imaging tools is paramount. Progress in diagnostic techniques, including novel molecular methods, the expanding utilization and accuracy of bedside ultrasound, and the emergence of Artificial Intelligence, coupled with an improved comprehension of lung microbiota and host-pathogen interactions, continues to enhance our capability to accurately and swiftly identify HAP and its causative agents. This advancement enables the refinement of treatment strategies and facilitates the implementation of precision medicine approaches.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"423-433"},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statement of Retraction: Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial. 撤回声明：伊维菌素在COVID-19治疗中的作用（IRICT）：单中心、适应性、随机、双盲、安慰剂对照临床试验。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-06-04 DOI: 10.1080/14787210.2024.2362097

引用次数: 0

Indian consensus on the managemeNt of carbapenem-resistant enterobacterales infection in critically ill patients II (ICONIC II). 印度重症患者耐碳青霉烯类肠杆菌感染管理共识 II（ICONIC II）。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-27 DOI: 10.1080/14787210.2024.2360116

Rajeev Soman, Balaji Veeraraghavan, Ashit Hegde, Subhash Varma, Subhash Todi, R K Singh, Vasant Nagavekar, Camilla Rodrigues, Subramanian Swaminathan, V Ramsubramanian, Abdul Ansari, Dhruva Chaudhry, Amullya Pednekar, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate

{"title":"Indian consensus on the managemeNt of carbapenem-resistant enterobacterales infection in critically ill patients II (ICONIC II).","authors":"Rajeev Soman, Balaji Veeraraghavan, Ashit Hegde, Subhash Varma, Subhash Todi, R K Singh, Vasant Nagavekar, Camilla Rodrigues, Subramanian Swaminathan, V Ramsubramanian, Abdul Ansari, Dhruva Chaudhry, Amullya Pednekar, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate","doi":"10.1080/14787210.2024.2360116","DOIUrl":"10.1080/14787210.2024.2360116","url":null,"abstract":"Introduction: The rising challenge of carbapenem-resistant Enterobacterales (CRE) infections in Indian healthcare settings calls for clear clinical guidance on the management of these infections. The Indian consensus on the management of CRE infection in critically ill patients (ICONIC-II) is a follow-up of the ICONIC-I study, which was undertaken in 2019.Areas covered: A modified Delphi method was used to build expert consensus on CRE management in India, involving online surveys, face-to - face expert meetings, and a literature review. A panel of 12 experts was formed to develop potential clinical consensus statements (CCSs), which were rated through two survey rounds. The CCSs were finalized in a final face-to - face discussion. The finalized CCSs were categorized as consensus, near consensus, and no consensus.Expert opinion: The outcomes included 46 CCSs (consensus: 40; near consensus: 3; and no consensus: 3). The expert panel discussed and achieved consensus on various strategies for managing CRE infections, emphasizing the significance of existing and emerging resistance mechanisms, prompt and tailored empiric therapy, and use of combination therapies. The consensus statements based on the collective expertise of the panel can potentially assist clinicians in the management of CRE infections that lack high-level evidence.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"453-468"},"PeriodicalIF":4.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141093207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications. 依拉维辛：体外活性、临床疗效和实际应用的全面回顾。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-08 DOI: 10.1080/14787210.2024.2351552

Po-Yu Huang, Chi-Kuei Hsu, Hung-Jen Tang, Chih-Cheng Lai

{"title":"Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications.","authors":"Po-Yu Huang, Chi-Kuei Hsu, Hung-Jen Tang, Chih-Cheng Lai","doi":"10.1080/14787210.2024.2351552","DOIUrl":"10.1080/14787210.2024.2351552","url":null,"abstract":"Introduction: The escalating threat of multidrug-resistant organisms necessitates constant exploration for novel antimicrobial agents. Eravacycline has emerged as a promising solution due to its unique chemical structure, which enhances potency and expands its spectrum of activity.Area covered: This review provides a thorough examination of eravacycline, encompassing its in vitro activity against Gram-positive and Gram-negative aerobes, carbapenem-non-susceptible organisms, anaerobes, and other bacterial strains. Additionally, it evaluates evidence from clinical studies to establish its clinical effect and safety.Expert opinion: Eravacycline, a synthetic fluorocycline, belongs to the tetracyclines class. Similar to other tetracycline, eravacycline exerts its antibacterial action by reversibly binding to the bacterial ribosomal 30S subunit. Eravacycline demonstrates potent in vitro activity against many Gram-positive and Gram-negative aerobes, anaerobes, and multidrug-resistant organisms. Randomized controlled trials and its associated meta-analysis affirm eravacycline's efficacy in treating complicated intra-abdominal infections. Moreover, real-world studies showcase eravacycline's adaptability and effectiveness in diverse clinical conditions, emphasizing its utility beyond labeled indications. Despite common gastrointestinal adverse events, eravacycline maintains an overall favorable safety profile, reinforcing its status as a tolerable antibiotic. However, ongoing research is essential for refining eravacycline's role, exploring combination therapy, and assessing its performance against biofilms, in combating challenging bacterial infections.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"387-398"},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative strategies for the surveillance, prevention, and management of pediatric infections applied to low-income settings. 适用于低收入环境的儿科感染监测、预防和管理创新战略。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-17 DOI: 10.1080/14787210.2024.2354839

David Torres-Fernandez, Jessica Dalsuco, Justina Bramugy, Quique Bassat, Rosauro Varo

{"title":"Innovative strategies for the surveillance, prevention, and management of pediatric infections applied to low-income settings.","authors":"David Torres-Fernandez, Jessica Dalsuco, Justina Bramugy, Quique Bassat, Rosauro Varo","doi":"10.1080/14787210.2024.2354839","DOIUrl":"10.1080/14787210.2024.2354839","url":null,"abstract":"Introduction: Infectious diseases still cause a significant burden of morbidity and mortality among children in low- and middle-income countries (LMICs). There are ample opportunities for innovation in surveillance, prevention, and management, with the ultimate goal of improving survival.Areas covered: This review discusses the current status in the use and development of innovative strategies for pediatric infectious diseases in LMICs by focusing on surveillance, diagnosis, prevention, and management. Topics covered are: Minimally Invasive Tissue Sampling as a technique to accurately ascertain the cause of death; Genetic Surveillance to trace the pathogen genomic diversity and emergence of resistance; Artificial Intelligence as a multidisciplinary tool; Portable noninvasive imaging methods; and Prognostic Biomarkers to triage and risk stratify pediatric patients.Expert opinion: To overcome the specific hurdles in child health for LMICs, some innovative strategies appear at the forefront of research. If the development of these next-generation tools remains focused on accessibility, sustainability and capacity building, reshaping epidemiological surveillance, diagnosis, and treatment in LMICs, can become a reality and result in a significant public health impact. Their integration with existing healthcare infrastructures may revolutionize disease detection and surveillance, and improve child health and survival.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"413-422"},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140915980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An assessment of the index of rational drug prescribing for severe acute respiratory infections among hospitalised children in Northern Nigeria: a retrospective study. 尼日利亚北部住院儿童严重急性呼吸道感染合理用药指数评估：一项回顾性研究。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-06-01 Epub Date: 2024-02-09 DOI: 10.1080/14787210.2024.2307913

Aliyu Sulaiman, Mohammad Alfa Isah, Abubakar Usman

{"title":"An assessment of the index of rational drug prescribing for severe acute respiratory infections among hospitalised children in Northern Nigeria: a retrospective study.","authors":"Aliyu Sulaiman, Mohammad Alfa Isah, Abubakar Usman","doi":"10.1080/14787210.2024.2307913","DOIUrl":"10.1080/14787210.2024.2307913","url":null,"abstract":"Background: This study evaluated drug use pattern among hospitalized children with severe acute respiratory infection (SARI) in Nigeria.Research design and methods: A retrospective assessment of prescribed medicines for children aged 13 years and below who were admitted and treated for SARI from 1 January 2016 to 31 December 2018 was conducted. The WHO prescribing indicators and the Index of Rational Drug Prescribing were used to evaluate prescriptions.Results: A total of 259 patients were included, mostly diagnosed with bronchopneumonia (56%). A summary of WHO-core prescribing indicators showed the average number of drugs per encounter was 3.9, medicines prescribed by generic name was 82.1%, and an encounter with at least an antibiotic was 99.7%. The percentage of drugs prescribed from the Essential Medicine List for children was 79%. The most frequently prescribed pharmacological class of medicines was antibiotics (41.4%). Cephalosporins (40.0%), aminoglycosides (34.1%), and penicillins (21.5%) were the most commonly prescribed antibiotic classes. Gentamicin (34.1%) and cefuroxime (21.5%) were the most commonly prescribed antibiotics.Conclusions: Drug prescribing for hospitalized children with SARI was suboptimal, especially with regard to polypharmacy, antibiotics, and injection use. Interventions to promote rational use of medicines including antimicrobial stewardship interventions are recommended.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"479-486"},"PeriodicalIF":5.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond resistance: assessing sulbactam-Durlobactam’s role in Today’s clinical landscape 超越耐药性：评估舒巴坦-杜鲁巴坦在当今临床中的作用

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-02 DOI: 10.1080/14787210.2024.2351026

Ahmad Z. Al Meslamani

引用次数: 0

Clostridioides difficile infection in inflammatory bowel disease: a clinical review 炎症性肠病中的艰难梭菌感染：临床综述

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-02 DOI: 10.1080/14787210.2024.2347955

Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen

引用次数: 0

Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China. 基于中国一项多中心、大规模、回顾性队列研究的 MDR/RR-TB 治疗结果优化药物建议。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-01 Epub Date: 2024-01-22 DOI: 10.1080/14787210.2024.2303032

Lin Fan, Ming Yang, Yu-Tong Han, Fei Ren, Hua Wang, Jin-Bao Ma, Guo-Hui Zhu, Yan-Jun Xiong, Xin-Xin Fan, Su-Xia Chen, Hao-Yu Wu, Wen-Wen Sun, Shao-Jun Zhang, Hui Ke, Xiao-Hong Cheng, Biao Xu, Yu Chen, Chang Chen

{"title":"Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China.","authors":"Lin Fan, Ming Yang, Yu-Tong Han, Fei Ren, Hua Wang, Jin-Bao Ma, Guo-Hui Zhu, Yan-Jun Xiong, Xin-Xin Fan, Su-Xia Chen, Hao-Yu Wu, Wen-Wen Sun, Shao-Jun Zhang, Hui Ke, Xiao-Hong Cheng, Biao Xu, Yu Chen, Chang Chen","doi":"10.1080/14787210.2024.2303032","DOIUrl":"10.1080/14787210.2024.2303032","url":null,"abstract":"Objective: With the change in drug-resistant pattern, MDR/RR-TB was faced with underlying changes in regimens. A multi-center, large-scale, retrospective study performed aims to provide a recommendation of drug selection on optimization of outcome for the patients.Method: The study was conducted in six TB-specialized hospitals in China. Patients were included from 2018-2021 and followed up throughout the treatment. Using a multivarariable and propensity score-matched logistic regression analysis, we evaluated associations between outcomes and drug use, as well as clinical characteritics.Results: Of 3112 patients, 74.29% had treatment sucess, 14.52% lost to follow-up, 9.67% failure, and 1.51% died. Treatment success was positively associated with Bedaquiline(Bdq), Linezolid(Lzd), and Cycloserin(Cs). Capreomycin(Cm) increased the risk of unfavorable outcomes. other drugs such as Amikacin(Amk) and clofazimine had no significant effect on outcomes. If isolates were susceptible to fluoroquinolones(FQs), FQs could decrease the risk of unfavorable outcomes.Conclusions: The recommendation order for the treatment of MDR/RR-TB is Bdq, Lzd, and Cs. FQs were decreased in use intensity. Injection drugs, whether Amk or Cm, are not recommended.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"353-363"},"PeriodicalIF":4.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-cancerous complications in HTLV-1 carriers. HTLV-1 携带者的非癌症并发症。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-05-01 Epub Date: 2024-04-01 DOI: 10.1080/14787210.2024.2336547

Akihiro Ohmoto, Shigeo Fuji

{"title":"Non-cancerous complications in HTLV-1 carriers.","authors":"Akihiro Ohmoto, Shigeo Fuji","doi":"10.1080/14787210.2024.2336547","DOIUrl":"10.1080/14787210.2024.2336547","url":null,"abstract":"Introduction: Human T-cell leukemia virus type 1 (HTLV-1) carriers may develop adult T-cell leukemia (ATL), or HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP). The evidence is limited regarding other diseases potentially associated with HTLV-1, such as HTLV-1-associated autoimmune diseases.Area covered: We summarized the available information on complications associated with HTLV-1 infection.Expert opinion: Previous studies showed that HTLV-1 carriers have an increased incidence of collagen diseases including Sjögren's syndrome, as well as dysthyroidism, diabetes mellitus, and atherosclerosis. Furthermore, cognitive deficits are observed in asymptomatic carriers and in symptomatic carriers who develop HAM/TSP. It is hypothesized that altered immunoregulation occurs as a result of persistent HTLV-1 infection. A systematic review and meta-analysis demonstrated that HTLV-1 infection itself has an adverse impact on overall survival. ATL alone cannot entirely explain the adverse impact of HTLV-1 infection on overall mortality, because the incidence is low, and therefore HTLV-1-associated diseases as a whole may contribute to the inferior clinical outcome. However, there are insufficient data to determine the causal relationship between HTLV-1 infection and each complication. While non-cancerous events linked to HTLV-1 infection are not fatal, they are likely to reduce quality of life. Large prospective studies should be conducted by international collaborators.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"307-316"},"PeriodicalIF":5.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0